Drug
Zenagamtide
Zenagamtide: highest development phase Phase 3, developed by Novo Nordisk. 4 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Novo Nordisk
Trials
| Drug | Phase | Indication |
|---|---|---|
| Zenagamtide NCT07931547 | Phase 3 | Type 2 Diabetes |
| Zenagamtide NCT07931495 | Phase 3 | Diabetes Mellitus, Type 2 |
| Zenagamtide NCT07931573 | Phase 3 | Type 2 Diabetes |
| Zenagamtide NCT07931599 | Phase 3 | Diabetes Mellitus, Type 2 |
Latest
No recent events.
Follow Zenagamtide on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.